Quarterly Updates5 May 2026, 06:31 pm
Sandu Pharma: Deviation Statement for Q ended 31.03.2026
AI Summary
Sandu Pharmaceuticals Ltd has filed a statement of deviation and variation of funds for the quarter ended March 31, 2026, as per Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The filing pertains to preferential issues of equity shares via private placement in 2021 and 2022. The audit committee has reviewed and approved the statement, and the auditors have provided no comments. There was no deviation or variation in the use of funds raised.
Key Highlights
- Sandu Pharma reports no deviation in use of funds raised through preferential issues.
- Report filed for the quarter ended March 31, 2026.
- Audit Committee reviewed and approved the statement.
- No comments were provided by the auditors.
Price Impact
More from SANDUPHQ
More in Quarterly Updates